Rituximab-induced Serum Sickness in Lymphoma: A Case Report

Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):e693-e695. doi: 10.1016/j.clml.2021.04.010. Epub 2021 Apr 16.

Authors

B Navarro-Matilla¹, A Ramirez-Garcia², A Sancho-Lopez³, J M Mateos-Pérez¹, A Plaza-Lopez⁴, M A De Laiglesia¹

Affiliations

¹ Haematology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
² Clinical Pharmacology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. Electronic address: almudena.ramirez@salud.madrid.org.
³ Clinical Pharmacology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
⁴ Immunology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.

PMID: 34006490
DOI: 10.1016/j.clml.2021.04.010

No abstract available

Keywords: Adverse effect; Anti-rituximab antibodies; Biosimilar; Polyarthritis; Rituximab.

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Humans
Lymphoma / complications*
Lymphoma / drug therapy*
Male
Rituximab / adverse effects*
Serum Sickness / chemically induced

Substances

Antineoplastic Agents, Immunological
Rituximab